for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SCYNEXIS Inc

SCYX.OQ

Latest Trade

1.15USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.36

 - 

1.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.15
Open
--
Volume
--
3M AVG Volume
5.25
Today's High
--
Today's Low
--
52 Week High
1.90
52 Week Low
0.36
Shares Out (MIL)
55.71
Market Cap (MIL)
64.06
Forward P/E
-1.19
Dividend (Yield %)
--

Latest Developments

More

Scynexis Reports Q2 Loss Per Share $0.16

Scynexis Announces Special Protocol Assessment (SPA) Agreement With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp

Scynexis Q1 Loss Per Share $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SCYNEXIS Inc

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry

Biotechnology & Drugs

Contact Info

1 Evertrust Plz Fl 13

+1.201.8845485

http://www.scynexis.com/

Executive Leadership

Pamela J. Kirby

Chairman of the Board

Marco Taglietti

President, Chief Executive Officer, Director

Eric S. Francois

Chief Financial Officer

Nkechi Azie

Vice President - Clinical Development

Scott A. Sukenick

General Counsel

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.580

2017

-0.940

2018

-0.280

2019(E)

-0.966
Price To Earnings (TTM)
--
Price To Sales (TTM)
257.29
Price To Book (MRQ)
6.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
140.28
LT Debt To Equity (MRQ)
140.28
Return on Investment (TTM)
-73.72
Return on Equity (TTM)
-58.55

Latest News

BRIEF-Scynexis Q1 Loss Per Share $0.12

* SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Caxton Corporation Reports 9.99 Percent Passive Stake In Scynexis Inc As Of March 6, 2018 - SEC Filing

* CAXTON CORPORATION REPORTS 9.99 PERCENT PASSIVE STAKE IN SCYNEXIS INC AS OF MARCH 6, 2018 - SEC FILING Source text (http://bit.ly/2tII9WD) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants

* SCYNEXIS ANNOUNCES PRICING OF $30.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-Scynexis Inc Presents New In Vivo Data Highlighting The Potential Of Scy-078

* SCYNEXIS PRESENTS NEW IN VIVO DATA HIGHLIGHTING THE POTENTIAL OF SCY-078 USED IN COMBINATION FOR THE TREATMENT OF ASPERGILLUS INFECTIONS AT AAA 2018 Source text for Eikon: Further company coverage:

BRIEF-Scynexis Provides Corporate And SCY-078 Pipeline Update

* SCYNEXIS INC - INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update

BRIEF-Scynexis presents new data related to SCY-078​

* Scynexis Inc - data demonstrates broad activity and potential clinical utility of SCY-078 against invasive candida and aspergillus infections Source text for Eikon: Further company coverage:

BRIEF-Scynexis CEO Marco Taglietti​ buys 10,000 shares of co's common stock on Aug 15

* Scynexis Inc CEO Marco Taglietti reports purchase of 10,000 shares of co's common stock on Aug 15 at $1.61 per share - SEC filing Source text: (http://bit.ly/2wj4Cck) Further company coverage:

BRIEF-Scynexis Q2 loss per share $0.16

* Scynexis reports second quarter 2017 financial results and provides company update

BRIEF-SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

* SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

BRIEF-Scynexis Q1 loss per share $0.19

* Scynexis reports first quarter 2017 financial results and provides update on iv formulation development status

BRIEF-Scynexis says to present SCY-078 data on lead anti-infective candidate

* Scynexis inc says to present scy-078 data on novel lead anti-infective candidate

BRIEF-Scynexis announces appointment Marion Mccourt to its board

* Scynexis announces appointment of industry veteran Marion Mccourt to its board of directors

BRIEF-SCYNEXIS Inc reports Q3 2016 financial results

* SCYNEXIS, Inc. reports third quarter 2016 financial results and provides company update

BRIEF-SCYNEXIS: HC Wainwright starts with $14 PT; rating 'buy'

* HC Wainwright starts with $14 price target; rating buy Further company coverage:

BRIEF-Scynexis enters into loan and security agreement with Solar Capital

* On September 30, 2016, Co entered into loan and security agreement with Solar Capital Ltd. - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up